241 related articles for article (PubMed ID: 19207869)
1. Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model.
Song SH; Kwak IS; Yang BY; Lee DW; Lee SB; Lee MY
Nephrology (Carlton); 2009 Apr; 14(2):155-63. PubMed ID: 19207869
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor (PPAR)-γ Agonist, Attenuates Inflammation Via NF-κB Inhibition in Lipopolysaccharide-Induced Peritonitis.
Zhang YF; Zou XL; Wu J; Yu XQ; Yang X
Inflammation; 2015 Dec; 38(6):2105-15. PubMed ID: 26047949
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
5. PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1.
Zhang Y; Feng J; Wang Q; Zhao S; Xu J; Li H
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29871973
[TBL] [Abstract][Full Text] [Related]
6. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.
Yao Q; Ayala ER; Qian JQ; Stenvinkel P; Axelsson J; Lindholm B
Clin Nephrol; 2007 Nov; 68(5):295-301. PubMed ID: 18044261
[TBL] [Abstract][Full Text] [Related]
7. [Effects of all-trans retinoic acid on the expression of TGF-beta 1 and COL-I in rat model of peritoneal dialysis].
Wang GH; Tang XH; Ma YL; Gao YC
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 39(4):575-8. PubMed ID: 18798497
[TBL] [Abstract][Full Text] [Related]
8. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model.
Kim CD; Kwon HM; Park SH; Oh EJ; Kim MH; Choi SY; Choi MJ; Kim IS; Park MS; Kim YJ; Kim YL
Ther Apher Dial; 2007 Feb; 11(1):56-64. PubMed ID: 17309576
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.
Efrati S; Berman S; Chachashvili A; Cohen N; Siman-Tov Y; Averbukh Z; Weissgarten J
Nephrology (Carlton); 2009 Apr; 14(2):189-97. PubMed ID: 19143945
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
[TBL] [Abstract][Full Text] [Related]
11. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage.
Nakamura S; Niwa T
J Am Soc Nephrol; 2005 Jan; 16(1):144-50. PubMed ID: 15563557
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.
Yao Q; Pawlaczyk K; Ayala ER; Kuzlan M; Styszynski A; Breborowicz A; Heimburger O; Qian J; Stenvinkel P; Axelsson J; Lindholm B
Blood Purif; 2006; 24(5-6):575-82. PubMed ID: 17124426
[TBL] [Abstract][Full Text] [Related]
13. The effects of peroxisome proliferator-activated receptor-gamma agonist on a murine model of experimental allergic rhinitis.
Jeon EJ; Lee SK; Park YS; Kim DH; Yum JH; Park CS
Otolaryngol Head Neck Surg; 2008 Jul; 139(1):124-30. PubMed ID: 18585574
[TBL] [Abstract][Full Text] [Related]
14. Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats.
Subeq YM; Ke CY; Lin NT; Lee CJ; Chiu YH; Hsu BG
Cytokine; 2011 Feb; 53(2):223-30. PubMed ID: 21129996
[TBL] [Abstract][Full Text] [Related]
15. Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGF-beta1 and VEGF expression in rat peritoneal mesothelial cells.
Mizuiri S; Ohashi Y; Hemmi H; Arita M; Yamada K; Aoki T; Miyagi M; Sakai K; Aikawa A
Am J Nephrol; 2009; 30(3):295-302. PubMed ID: 19546527
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
Liu D; Zeng BX; Zhang SH; Yao SL
Inflamm Res; 2005 Nov; 54(11):464-70. PubMed ID: 16307220
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
[TBL] [Abstract][Full Text] [Related]
19. [The role of TGF-beta1/Smads in the development of peritoneal fibrosis induced by high glucose peritoneal dialysate and LPS].
Dou XR; Yu XQ; Li XY; Chen WF; Hao WK; Jia ZJ; Peng WX; Wang X; Yin PD; Wang WJ; Zheng ZH
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2613-8. PubMed ID: 16321321
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
